Immunovant, Inc. IMVT Accrued expenses and other current liabilities
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept imvt:IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilitiesCurrent.
The official record: Immunovant, Inc.’s 10-Q, filed February 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunovant, Inc.'s accrued expenses and other current liabilities.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunovant, Inc.'s accrued expenses and other current liabilities?
- Immunovant, Inc. (IMVT) reported accrued expenses and other current liabilities of $756K in Q4 2025.
- How has Immunovant, Inc.'s accrued expenses and other current liabilities changed year-over-year?
- Immunovant, Inc.'s accrued expenses and other current liabilities decreased by 81.7% year-over-year, from $4.12M to $756K.